GENE ONLINE|News &
Opinion
Blog

2021-01-29| Asia-PacificCOVID-19

Japan’s Shionogi Grants US Company the Rights to Develop a Repurposed Allergic Rhinitis Drug as a COVID-19 Cure

by Tyler Chen
Share To

COVID-19 drugs have become a huge market where every company is eager to enter. However, due to the high R&D cost and the highly competitive market, it’s challenging to squeeze in without innovative technology or promising drugs at hand.

On January 26th, Japan’s Shionogi agreed to grant BioAge Labs, a U.S. biotech, the development and marketing rights of its potential COVID-19 treatment BGE-175 (S-555739) in the U.S., Europe, and the United Kingdom.

 

BGE-175 – An Allergic Rhinitis Treatment

BGE-175 is a DP1 receptor antagonist that can inhibit PGD2 signaling. It was originally developed for treating allergic rhinitis but was later found out to be a promising medicine for boosting the immune system of COVID-19 patients, especially elders, by drug repurposing.

The safety and tolerability of BGE-175 have been evaluated in clinical trials comprising over 2,400 subjects, and the drug also demonstrated high selectivity and affinity to the DP1 receptor. As DP1 is identified as a target to tackle age-related declines in immune function, BGE-175 might be able to build up a person’s immune system while reducing the severity of infectious diseases such as COVID-19.

Furthermore, a study from the University of Iowa showed that the mortality rate of COVID-19 mouse models improves after the injection of DP1 receptor antagonists. Besides, the viral load was substantially plummeted in the lungs, all in all displaying the possibility of BGE-175.

 

Agreement Details

As per the agreement, in addition to enjoying exclusive rights in particular areas, BioAge Labs will also receive the option to license BGE-175 for other indications. Shionogi will receive an upfront payment, incentives upon reaching development and regulatory milestones and royalties. The price is currently not disclosed in the official news outlet.

As for the drug development, BioAge Labs is determined to launch the Phase 2 trial of BGE-175 for COVID-19 in the first half of 2021.

Related Article: Takeda, KSQ Join Forces to Identify NK Cell Targets For Cancer Therapies

References
  1. https://www.shionogi.com/global/en/news/2021/01/e-20210126.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
R&D
Modulation of Hematopoietic Stem Cell Composition Holds Promise for Immune System Revitalization
2024-04-03
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
LATEST
Taiwan Biotech Delegation Leads International Exchange with Phoenix Biotech Community and Mayo Clinic
2024-05-29
BIO 2024 Sets the Stage for Taiwan’s Biotech Industry to Shine
2024-05-29
GV Innovation High-Value Niche Market Transformation Project
2024-05-29
ASCO 2024: Covering Skin Cancer, Bispecific Antibody Treatment, TIGIT-Targeted Drugs, Radiotherapy and More
2024-05-29
Major Cancer Research Publications at the 2024 American Society of Clinical Oncology Annual Meeting
2024-05-28
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
2024-05-27
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
EVENT
Scroll to Top